Ashfield Capital Partners LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,428 shares of the company’s stock, valued at approximately $208,000.

A number of other hedge funds also recently bought and sold shares of LLY. Accredited Investors Inc. increased its holdings in shares of Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its holdings in shares of Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after acquiring an additional 19 shares during the last quarter. Oakworth Capital Inc. increased its holdings in shares of Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares during the last quarter. Sfmg LLC increased its holdings in shares of Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after acquiring an additional 20 shares during the last quarter. Finally, Jackson Grant Investment Advisers Inc. increased its holdings in shares of Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after acquiring an additional 24 shares during the last quarter. 76.30% of the stock is currently owned by institutional investors.

In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the transaction, the senior vice president now directly owns 124,522 shares in the company, valued at approximately $10,766,172.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders sold a total of 651,088 shares of company stock worth $56,439,586 over the last quarter. Company insiders own 0.20% of the company’s stock.

A number of research firms have recently commented on LLY. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Jefferies Group reiterated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Leerink Swann increased their price objective on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $105.00 price objective (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $90.25.

Eli Lilly and Company (NYSE:LLY) opened at $85.74 on Thursday. The stock has a market capitalization of $95,475.95, a P/E ratio of 21.20, a P/E/G ratio of 1.79 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a 12 month low of $72.68 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. analysts expect that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.62%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.

TRADEMARK VIOLATION NOTICE: “Ashfield Capital Partners LLC Purchases New Stake in Eli Lilly and Company (LLY)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/21/ashfield-capital-partners-llc-purchases-new-stake-in-eli-lilly-and-company-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.